Australia markets closed

Ascentage Pharma Group International (6855.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
25.350+0.050 (+0.20%)
At close: 04:08PM HKT
Currency in HKD

Valuation measures4

Market cap (intra-day) 7.96B
Enterprise value 8.74B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)29.94
Price/book (mrq)122.60
Enterprise value/revenue 36.64
Enterprise value/EBITDA -8.41

Trading information

Stock price history

Beta (5Y monthly) 1.16
52-week change 324.32%
S&P500 52-week change 324.96%
52-week high 329.800
52-week low 315.420
50-day moving average 319.718
200-day moving average 322.704

Share statistics

Avg vol (3-month) 31.73M
Avg vol (10-day) 33.31M
Shares outstanding 5314.65M
Implied shares outstanding 6314.65M
Float 8206.71M
% held by insiders 132.30%
% held by institutions 17.10%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in CNY.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-671.10%

Management effectiveness

Return on assets (ttm)-20.92%
Return on equity (ttm)-386.28%

Income statement

Revenue (ttm)221.98M
Revenue per share (ttm)0.79
Quarterly revenue growth (yoy)-30.40%
Gross profit (ttm)N/A
EBITDA -812.82M
Net income avi to common (ttm)-925.64M
Diluted EPS (ttm)-3.520
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.1B
Total cash per share (mrq)3.79
Total debt (mrq)1.8B
Total debt/equity (mrq)2,542.18%
Current ratio (mrq)1.44
Book value per share (mrq)0.21

Cash flow statement

Operating cash flow (ttm)-726.08M
Levered free cash flow (ttm)-706.12M